Get the Stockscreener App
19.34
0.92%
-0.18
After Hours:
19.34
Immunovant Inc Stock (IMVT) Latest News
Guggenheim cuts Immunovant stock target to $44, maintains Buy By Investing.com - Investing.com Australia
Guggenheim cuts Immunovant stock target to $44, maintains Buy - MSN
IMVT Q3 Loss Wider Than Expected, Stock Down, Pipeline in Focus - MSN
Immunovant (NASDAQ:IMVT) Price Target Cut to $44.00 by Analysts at Guggenheim - Defense World
Immunovant FY2025 EPS Estimate Raised by Leerink Partnrs - Defense World
Immunovant (NASDAQ:IMVT) Reaches New 12-Month Low on Disappointing Earnings - Defense World
Immunovant’s (IMVT) Buy Rating Reiterated at HC Wainwright - Defense World
Immunovant (NASDAQ:IMVT) Reaches New 12-Month Low Following Weak Earnings - MarketBeat
Immunovant, Inc. (NASDAQ:IMVT) Receives $47.00 Consensus PT from Analysts - Defense World
Oppenheimer Adjusts Price Target on Immunovant to $54 From $53, Keeps Outperform Rating - Marketscreener.com
abrdn plc Grows Stake in Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Immunovant FY2025 EPS Estimate Lifted by Leerink Partnrs - MarketBeat
Immunovant, Inc. (NASDAQ:IMVT) Given Consensus Rating of "Buy" by Analysts - MarketBeat
HC Wainwright Reaffirms Buy Rating for Immunovant (NASDAQ:IMVT) - MarketBeat
Immunovant Inc [NASDAQ: IMVT] Sees Decrease in Stock Value - Knox Daily
Immunovant (NASDAQ:IMVT) Releases Quarterly Earnings Results, Misses Estimates By $0.08 EPS - MarketBeat
Immunovant (NASDAQ:IMVT) Shares Down 5% After Earnings Miss - MarketBeat
IMVT’s Market Whiplash: -17.80% YTD Decline, -17.34% Plunge in 30 Days - The InvestChronicle
Immunovant (NASDAQ:IMVT) Stock Price Down 5% on Disappointing Earnings - Defense World
Immunovant Reports Progress Amid Increased R&D Costs - TipRanks
Immunovant (NASDAQ:IMVT) Sets New 1-Year LowHere's What Happened - MarketBeat
Immunovant's Fiscal Q3 Loss Widens -February 06, 2025 at 07:40 am EST - Marketscreener.com
Immunovant Inc. (IMVT) reports earnings - Quartz
Immunovant Reports Financial Results for the Quarter Ended December 31, 2024 - The Manila Times
ForexTV | Small Business Resources - ForexTV.com
Immunovant's Massive $825M War Chest Fuels Race for Breakthrough Autoimmune Treatments - StockTitan
Immunovant (IMVT) Projected to Post Earnings on Thursday - MarketBeat
Investor’s Toolkit: Key Ratios for Assessing Immunovant Inc (IMVT)’s Performance - The Dwinnex
Immunovant (NASDAQ:IMVT) Raised to Strong-Buy at Cantor Fitzgerald - MarketBeat
Immunovant Inc (IMVT) may enjoy gains as insiders got busy in the recent days - Knox Daily
Prepare Yourself for Liftoff: Immunovant Inc (IMVT) - SETE News
Immunovant Enters Oversold Territory (IMVT) - Nasdaq
Immunovant (NASDAQ:IMVT) Upgraded at Cantor Fitzgerald - Defense World
Here’s Why Immunovant, Inc. (IMVT) Will Double in 2025 - Insider Monkey
12 Stocks That Will Double in 2025 - Insider Monkey
Immunovant registers shares for selling stockholders - MSN
Immunovant's chief medical officer Michael Geffner sells $62,678 in stock - MSN
Immunovant CTO Jay Stout sells $51,780 in stock - MSN
Immunovant stock hits 52-week low at $22.39 amid market challenges - MSN
Immunovant (NASDAQ:IMVT) Reaches New 12-Month Low on Insider Selling - Defense World
Immunovant stock hits 52-week low at $22.39 amid market challenges By Investing.com - Investing.com South Africa
Immunovant (NASDAQ:IMVT) Sets New 52-Week Low Following Insider Selling - MarketBeat
Immunovant (NASDAQ:IMVT) vs. Genfit (NASDAQ:GNFT) Head to Head Analysis - Defense World
Immunovant registers shares for selling stockholders By Investing.com - Investing.com Australia
Insider Selling: Immunovant, Inc. (NASDAQ:IMVT) Insider Sells 2,657 Shares of Stock - MarketBeat
Jay S. Stout Sells 2,195 Shares of Immunovant, Inc. (NASDAQ:IMVT) Stock - MarketBeat
Immunovant's chief medical officer Michael Geffner sells $62,678 in stock By Investing.com - Investing.com Australia
2.27%
5.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):